FDA seeks treatment protocol for Protalix Gaucher's disease drug

07/6/2009 | Wall Street Journal, The

The FDA asked Protalix to submit a treatment protocol for prGCD, its experimental Gaucher's disease drug, in light of a manufacturing problem that is expected to reduce the supply of Genzyme's Cerezyme. Protalix and the agency are reportedly discussing parameters to increase patients' access to prGCD.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC